Materiovigilance: Concept, Structure and Emerging Perspective for Patient’s Safety in India

Abstract

There has been an escalation in the number, diversity, and complexity of medical devices. Regulation of these devices has also advanced due to the requirement of better regulatory perspective induced due to elevation in the number of adverse events associated with medical devices. All over the globe, various measures are undertaken to provide better safety to the patients along with attempts to improve the standard of medical devices. The initial and ultimate objective of the concept happens to be unfailingly to ensure patient safety as well as impart required guidance for both manufacturers and adept authorities enabling them to superintend cases coherently and appropriately. Materiovigilance programme of India (MvPI) was launched by the Drug Controller General of India at the Indian Pharmacopoeia commission (IPC) in Ghaziabad in 2015. The main purpose of this initiative is to monitor adverse events associated with medical devices in order to generate safety data, create awareness among the various stakeholders, and prescribe best practices for patient safety. Whilst the reforms in regulations have proposed policies and designs to elucidate, consolidate and accelerate the processes involved in manufacturing and importing medical devices to India, they consistently carry their challenges and limitations. To eliminate such complications the guidelines and regulations are anticipated to be implemented appropriately with the efficacious conclusion. India has been evident in matching with advancements in the World Medical Device regulation scenario, the current review at hand takes upon the question of ‘how successful has it been so far’?

Key words

diagnostics - adverse drug reactions - drug regulation - drug research

Publikationsverlauf

Eingereicht: 07. Februar 2020

Angenommen: 29. Mai 2020

Artikel online veröffentlicht:
03. August 2020

• References

• 1 Gupta SK. Medical Device Regulations: A Current Perspective. Journal of Young Pharmacists 2016; 8: 1
• 2 Rani S, Singh K. Materiovigilance: An emerging discipline. Int J Sci Res 2018; 7: 15-16
• 3 Meher BR. Materiovigilance: An Indian perspective. Perspectives in Clinical Research 2018; 9: 175
• 4 The Inidan Express, How Johnson and Johnson hip implants system went wrong. Available from https://indianexpress.com/article/explained/johnson-and-johnson-how-hip-implants-went-wrong-jp-nada-5331779 Accessed on November 11, 2019
• 5 Jarow JP, Baxley JH. Editors Medical Devices: US Medical Device regulation. Urologic Oncology: Seminars and Original Investigations. 2015. Elsevier;
• 6 Gupta P, Janodia MD, Jagadish PC. et al. Medical device vigilance systems: India, US, UK, and Australia. Medical Devices (Auckland, NZ) 2010; 3: 67
• 7 Hauser RG. Here we go again—another failure of postmarketing device surveillance. New England Journal of Medicine 2012; 366: 873-875
• 8 Shukla S, Gupta M, Pandit S. et al. Implementation of adverse event reporting for medical devices. Bull World Health Organ 2020; 98: 206-211
• 9 Hefflin BJ, Gross TP, Schroeder TJ. Estimates of medical device–associated adverse events from emergency departments. American Journal of Preventive Medicine 2004; 27: 246-253
• 10 Materiovigilance programme of India. 2019; p. 6. Available from http://www.mvpi.co.in/newsletter6/newsletter6.html#page/1, Accessed on December 21, 2019.
• 11 Datta P, Mukhopadhyay I, Selvaraj S. Medical devices manufacturing industry in India: Market structure, import intensity and regulatory mechanisms. ISID-PHFI Collaborative Research Centre, Institute for Studies in Industria. 2013
• 12 Mandal S, Mandal M. Evolution of Pharmacovigilance Programme: Present status in India. Pharma Times 2017; 49: 31-36
• 13 Kalaiselvan V, Srivastava S, Singh A. et al. Pharmacovigilance in India: Present scenario and future challenges. Drug Safety 2019; 42: 339-346
• 14 Mal DK, Ehsan I, Mukherjee B. MATERIOVIGILANCE and HAEMOVIGILANCE. Available from; https://www.asianhhm.com/healthcare-management/materiovigilance-haemovigilance Accessed on January 9, 2020
• 15 Materiovigilance Programme of India (MvPI), Indian Pharmacopoeia Commission, 2015 Available from https://ipc.gov.in/images/pdf/File572.pdf Accessed Dec, 2019
• 16 Singh K, Kanase H. Pharmacovigilance programme of India: The beginning, current status and recent progress. Adv Pharmacoepidemiol Drug Saf 2017; 6: 1-4
• 17 Kumar P, Kalaiselvan V, Kaur I. et al. Materiovigilance programme of India (MVPI): A step towards patient safety for medical devices. Eur J Biomed Pharm Sci 2016; 12: 497-501
• 18 Kalaiselvan V, Mishra P, Singh GN. Helpline facility to assist reporting of adverse drug reactions in India. WHO South-East Asia Journal of Public Health 2014; 3: 194
• 19 Lamph S. Regulation of medical devices outside the European Union. Journal of the Royal Society of Medicine 2012; 105 (1_suppl): 12-21
• 20 Gupta P, Janodia MD, Jagadish PC. et al. Medical device vigilance systems: India, US, UK, and Australia. Medical Devices (Auckland, NZ) 2010; 3: 67
• 21 European Commission Medical Device Regulation (MDR). Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on Medical Devices. Available from https://eurlex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32017R0745 Accessed on April 7, 2020
• 22 China NMPA Medical Device Regulations. Available from https://www.emergobyul.com/resources/regulations-china Accessed on April 7, 2020
• 23 Materiovigilance Programme of India (MvPI) Indian Pharmacopoeia Commisssion 2015. Available from http://www.mvpi.co.in/newsletter6/newsletter6.html#page/1, Accessed on October 26, 2019